I try to remind myselfThat every day that goes by without news increases the chances of some preliminary efficacy and PoC being seen.
But the long wait for data is always hard for biotech investors.
I would think we are very close to hearing the trial has ended due to more SAE's in the additional patients recruited at the 2x normal Docetaxel dose level or we will be waiting until January as they did not have any trial-halting SAE's at the 2x level and are now moving to the 3x level. While the former would not be a bad outcome in my view, the latter would be better since the more Docetaxel you can get into the body safely, the better the chances of killing off cancer cells.